The Australian medical sector is excited with the emergence of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing remarkable results in early trials for treating obesity. This treatment promises a substantial way to tackle excess weight, potentially outperforming existing solutions like semaglutide. While access is still pending and f

Regarding persistent problems getting asleep , medicated sleep aids can appear as a tempting solution . However, such should genuinely be regarded a last option , considering the potential drawbacks and the need of resolving the underlying reasons of one's sleep disorder. Investigating non-medication approaches , such as CBT and lifestyle modifica